COVID-19 Vaccination and Glomerulonephritis

Klomjit, Nattawat; Alexander, Mariam P.; Fervenza, Fernando C.; Zoghby, Ziad; Garg, Arvind; Hogan, Marie C.; Nasr, Samih H.; Minshar, Marwan Abu; Zand, Ladan

doi:10.1016/j.ekir.2021.09.008

Cited by 143 publications

(206 citation statements)

References 38 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“… 7 A recent case series reported a greater association between mRNA vaccines (BNT162b2 and Moderna) and kidney disease, presenting with mostly minimal change disease and IgA nephropathy. 8 , 9 AIN seems to be present in only a minority of cases. We present the case of a patient with AIN that needs hemodialysis, following the administration of the BNT162b2 COVID-19 vaccine and describe the immunological study and the workup to identify the stimulatory excipient.…”

Section: Introductionmentioning

confidence: 90%

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine

Mira¹,

Carvalho²,

Almeida³

et al. 2021

IJNRD

View full text Add to dashboard Cite

Background The development of vaccines to prevent COVID-19 breakouts came with highly positive results but some unexpected side effects. Rare side effects have been seen with the BNT162b2 SARS-CoV 2 vaccine. Case Presentation We present the case of a 45-year-old female patient who developed an acute kidney injury needing urgent hemodialysis one week after the second administration of the BNT162b2 SARS-CoV 2 vaccine. She developed a macular rash on her lower limbs and palms as well. A kidney biopsy was performed 10 days after vaccine inoculation, diagnosing acute interstitial nephritis and acute tubular necrosis with cellular casts. The patient was treated with three corticosteroid pulses followed by daily prednisolone. We witnessed clinical improvement 4 days after the initial corticosteroid treatment with progressive recovery of kidney function and hemodialysis withdrawal. After 2 weeks, the patient had recovered her kidney function. Immunophenotyping was performed, diagnosing a hypersensitivity to the vaccine and the polyethylene glycol excipient. Conclusion Patients may develop acute reactions to vaccines. In this case, symptoms seem to correlate significantly with its inoculation and, although this case had a favourable outcome, these side effects must be made aware for clinicians and patients.

show abstract

Section: Introductionmentioning

confidence: 90%

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine

Mira¹,

Carvalho²,

Almeida³

et al. 2021

IJNRD

View full text Add to dashboard Cite

show abstract

“…BNT16b2 and mRNA-1273 mRNA vaccines are among the most outstanding achievements in next-generation vaccine development that showed a significant role in filling the need for global vaccine demand. Both the vaccines are composed of lipid nanoparticles that show an efficacy of ~ 95% (Khurana et al 2021 ). Lipid nanoparticles have various advantages that make them suitable as a vehicle to deliver mRNAs, such as the biocompatibility to human use, stability during the passage, efficient encapsulation of the informant, and increased cellular uptake in vivo (Khurana et al 2021 ; Park et al 2021 ).…”

Section: Nano-based Vaccines In the Development Of A Potential Covid-19 Vaccinementioning

confidence: 99%

“…Both the vaccines are composed of lipid nanoparticles that show an efficacy of ~ 95% (Khurana et al 2021 ). Lipid nanoparticles have various advantages that make them suitable as a vehicle to deliver mRNAs, such as the biocompatibility to human use, stability during the passage, efficient encapsulation of the informant, and increased cellular uptake in vivo (Khurana et al 2021 ; Park et al 2021 ). The 5′ and 3′ untranslated regions of mRNA sequences can be engineered systematically to the nanoparticle to ensure efficient delivery (Zeng et al 2020 ).…”

Section: Nano-based Vaccines In the Development Of A Potential Covid-19 Vaccinementioning

confidence: 99%

See 1 more Smart Citation

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Simnani

Singh

Kaur³

2021

3 Biotech

View full text Add to dashboard Cite

The COVID-19 pandemic has endangered world health and the economy. As the number of cases is increasing, different companies have started developing potential vaccines using both traditional and nano-based platforms to overcome the pandemic. Several countries have approved a few vaccine candidates for emergency use authorization (EUA), showing significant effectiveness and inducing a robust immune response. Oxford-AstraZeneca, Pfizer-BioNTech’s BNT162, Moderna’s mRNA-1273, Sinovac’s CoronaVac, Johnson & Johnson, Sputnik-V, and Sinopharm’s vaccine candidates are leading the race. However, the SARS-CoV-2 is constantly mutating, making the vaccines less effective, possibly by escaping immune response for some variants. Besides, some EUA vaccines have been reported to induce rare side effects such as blood clots, cardiac injury, anaphylaxis, and some neurological effects. Although the COVID-19 vaccine candidates promise to overcome the pandemic, a more significant and clear understanding is needed. In this review, we brief about the clinical trial of some leading candidates, their effectiveness, and their neutralizing effect on SARS-CoV-2 variants. Further, we have discussed the rare side effects, different traditional and nano-based platforms to understand the scope of future development.

show abstract

“…mRNA vaccines trigger more potent immune responses and are associated with higher rates of glomerulonephritis than other vaccines. 1 Recently, there are many reports on either new diagnoses or relapses of glomerulonephritis after COVID-19 vaccinations. 1 IgA nephropathy was the most common glomerulonephritis associated with COVID-19 vaccination.…”

mentioning

confidence: 99%

Newly diagnosed IgA nephropathy with gross haematuria following COVID-19 vaccination

Horino

Sawamura

Inotani

et al. 2021

QJM: An International Journal of Medicine

View full text Add to dashboard Cite

COVID-19 Vaccination and Glomerulonephritis

Cited by 143 publications

References 38 publications

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Newly diagnosed IgA nephropathy with gross haematuria following COVID-19 vaccination

Contact Info

Product

Resources

About